Chinese medicine (600056.SH) subsidiary Chemical raw materials drug dependence tiamum approval for listing application

Wisdom Financial News APP News, China Medicine (600056.SH) announced that recently, its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received the approval and issuance of the market application approval notice for ezetimibe chemical raw materials by the National Medical Products Administration. This drug is mainly used for primary hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (or plant sterolemia). The approval of this raw material will further expand the company's product range and improve the layout of raw materials for cardiovascular products.